NO20030725D0 - Terapeutisk kombinasjon av CETP-inhibitor og atorvastatin - Google Patents

Terapeutisk kombinasjon av CETP-inhibitor og atorvastatin

Info

Publication number: NO20030725D0
Authority: NO; Norway
Prior art keywords: atorvastatin; therapeutic combination; cetp inhibitor; cetp; inhibitor
Prior art date: 2000-08-15

Application number

NO20030725A

Other languages

English (en)

Norwegian (no)

Inventor

Charles Lester Shear

Original Assignee

Pfizer Prod Inc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2000-08-15

Filing date

2003-02-14

Publication date

2003-02-14

2003-02-14 Application filed by Pfizer Prod Inc filed Critical Pfizer Prod Inc

2003-02-14 Publication of NO20030725D0 publication Critical patent/NO20030725D0/no

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/4015—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil having oxo groups directly attached to the heterocyclic ring, e.g. piracetam, ethosuximide
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

Health & Medical Sciences (AREA)
General Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Veterinary Medicine (AREA)
Medicinal Chemistry (AREA)
Public Health (AREA)
Pharmacology & Pharmacy (AREA)
Life Sciences & Earth Sciences (AREA)
Animal Behavior & Ethology (AREA)
Epidemiology (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Organic Chemistry (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Diabetes (AREA)
Hematology (AREA)
Obesity (AREA)
Cardiology (AREA)
Heart & Thoracic Surgery (AREA)
Vascular Medicine (AREA)
Urology & Nephrology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Medicines Containing Plant Substances (AREA)
Quinoline Compounds (AREA)
Plural Heterocyclic Compounds (AREA)

NO20030725A 2000-08-15 2003-02-14 Terapeutisk kombinasjon av CETP-inhibitor og atorvastatin NO20030725D0 (no)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US22523800P	2000-08-15	2000-08-15
PCT/IB2001/001309 WO2002013797A2 (en)	2000-08-15	2001-07-23	Therapeutic combination of a cetp inhibitor and atorvastatin

Publications (1)

Publication Number	Publication Date
NO20030725D0 true NO20030725D0 (no)	2003-02-14

Family

ID=22844100

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
NO20030725A NO20030725D0 (no)	2000-08-15	2003-02-14	Terapeutisk kombinasjon av CETP-inhibitor og atorvastatin

Country Status (27)

Country	Link
US (1)	US20020035125A1 (es)
EP (1)	EP1309329A2 (es)
JP (1)	JP2004506008A (es)
KR (1)	KR20030069983A (es)
CN (1)	CN1735416A (es)
AP (1)	AP2003002743A0 (es)
AU (1)	AU2001270937A1 (es)
BG (1)	BG107515A (es)
BR (1)	BR0113200A (es)
CA (1)	CA2419406A1 (es)
CZ (1)	CZ2003390A3 (es)
DZ (1)	DZ3409A1 (es)
EA (1)	EA200300155A1 (es)
EC (1)	ECSP034478A (es)
HR (1)	HRP20030104A2 (es)
HU (1)	HUP0303083A3 (es)
IL (1)	IL154348A0 (es)
IS (1)	IS6700A (es)
MX (1)	MXPA03001419A (es)
NO (1)	NO20030725D0 (es)
PA (1)	PA8525301A1 (es)
PE (1)	PE20020340A1 (es)
SK (1)	SK1742003A3 (es)
SV (1)	SV2003000600A (es)
TN (1)	TNSN01125A1 (es)
UY (1)	UY26883A1 (es)
WO (1)	WO2002013797A2 (es)

Families Citing this family (45)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US20030044459A1 (en) *	2001-09-04	2003-03-06	Pfizer Inc.	Biomodulated multiparticulate formulations
US7071210B2 (en)	2002-07-02	2006-07-04	Pfizer Inc.	CETP inhibitors in combination with antihypertensive agents and uses thereof
US20040053842A1 (en) *	2002-07-02	2004-03-18	Pfizer Inc.	Methods of treatment with CETP inhibitors and antihypertensive agents
KR20050088190A (ko) *	2002-12-20	2005-09-02	화이자 프로덕츠 인코포레이티드	콜레스테릴 에스터 전달 단백질 억제제 및 ｈｍｇ-ｃｏａ환원 효소 억제제를 포함하는 투약 형태
US20040132771A1 (en) *	2002-12-20	2004-07-08	Pfizer Inc	Compositions of choleseteryl ester transfer protein inhibitors and HMG-CoA reductase inhibitors
ATE461700T1 (de)	2002-12-20	2010-04-15	Pfizer Prod Inc	Dosierungsform enthaltend einen cetp-hemmer und einen hmg-coa reduktase hemmer
TWI393560B (zh) *	2003-05-02	2013-04-21	Japan Tobacco Inc	包含ｓ-〔２（〔〔１-（２-乙基丁基）環己基〕羰基〕胺基）苯基〕２-甲基丙烷硫酯及ｈｍｇ輔酶ａ還原酶抑制劑之組合
RS20050890A (en) *	2003-05-30	2007-12-31	Ranbaxy Laboratories Limited,	Substituted pyrrole derivatives
MXPA06001506A (es) *	2003-08-04	2006-05-15	Pfizer Prod Inc	Formas de dosificacion de inhibidores de la proteina de transferencia de colesteril ester e inhibidores de la hmg-coa reductasa.
EP2316447A1 (en)	2003-09-26	2011-05-04	Japan Tobacco, Inc.	Method of inhibiting remnant lipoprotein production
US7737295B2 (en) *	2004-04-13	2010-06-15	Merck Sharp & Dohme Corp.	CETP inhibitors
CA2601762A1 (en) *	2005-02-03	2006-08-10	Pfizer Products Inc.	Dosage forms providing controlled and immediate release of cholesteryl ester transfer protein inhibitors and immediate release of hmg-coa reductase inhibitors
US7737155B2 (en)	2005-05-17	2010-06-15	Schering Corporation	Nitrogen-containing heterocyclic compounds and methods of use thereof
EP3578177A1 (en)	2008-09-02	2019-12-11	Amarin Pharmaceuticals Ireland Limited	Pharmaceutical composition comprising eicosapentaenoic acid and nicotinic acid and methods of using same
US20110243940A1 (en)	2008-12-16	2011-10-06	Schering Corporation	Bicyclic pyranone derivatives and methods of use thereof
US20110245209A1 (en)	2008-12-16	2011-10-06	Schering Corporation	Pyridopyrimidine derivatives and methods of use thereof
SG10201610916SA (en)	2009-02-10	2017-02-27	Amarin Pharmaceuticals Ie Ltd	Use of eicosapentaenoic acid ethyl ester for treating hypertriglyceridemia
WO2010127103A1 (en)	2009-04-29	2010-11-04	Amarin Pharma, Inc.	Stable pharmaceutical composition and methods of using same
CN102413825A (zh)	2009-04-29	2012-04-11	阿马里纳股份公司	含有epa和心血管剂的药物组合物以及使用其的方法
CA2772378C (en)	2009-06-15	2019-04-02	Amarin Pharma, Inc.	Compositions and methods for lowering triglycerides without raising ldl-c levels in a subject on concomitant statin therapy
SG10201405994UA (en) *	2009-09-23	2014-10-30	Amarin Pharmaceuticals Ie Ltd	Pharmaceutical Composition Comprising Omega-3 Fatty Acid And Hydroxy-derivative Of A Statin And Methods Of Using Same
NZ611606A (en)	2010-11-29	2015-10-30	Amarin Pharmaceuticals Ie Ltd	Low eructation composition and methods for treating and/or preventing cardiovascular disease in a subject with fish allergy/hypersensitivity
US11712429B2 (en)	2010-11-29	2023-08-01	Amarin Pharmaceuticals Ireland Limited	Low eructation composition and methods for treating and/or preventing cardiovascular disease in a subject with fish allergy/hypersensitivity
US11291643B2 (en)	2011-11-07	2022-04-05	Amarin Pharmaceuticals Ireland Limited	Methods of treating hypertriglyceridemia
US20130131170A1 (en)	2011-11-07	2013-05-23	Amarin Pharmaceuticals Ireland Limited	Methods of treating hypertriglyceridemia
WO2013103958A1 (en)	2012-01-06	2013-07-11	Amarin Pharmaceuticals Ireland Limited	Compositions and methods for lowering levels of high-sensitivity (hs-crp) in a subject
BR112014032905B1 (pt)	2012-06-29	2022-02-22	Amarin Pharmaceuticals Ireland Limited	Uso de éster etílico do ácido eicosapentaenóico para redução do risco de morte cardiovascular, revascularização coronária e/ou angina instável em um indivíduo em terapia com estatina
WO2014074552A2 (en)	2012-11-06	2014-05-15	Amarin Pharmaceuticals Ireland Limited	Compositions and methods for lowering triglycerides without raising ldl-c levels in a subject on concomitant statin therapy
US20140187633A1 (en)	2012-12-31	2014-07-03	Amarin Pharmaceuticals Ireland Limited	Methods of treating or preventing nonalcoholic steatohepatitis and/or primary biliary cirrhosis
US9814733B2 (en)	2012-12-31	2017-11-14	A,arin Pharmaceuticals Ireland Limited	Compositions comprising EPA and obeticholic acid and methods of use thereof
US9452151B2 (en)	2013-02-06	2016-09-27	Amarin Pharmaceuticals Ireland Limited	Methods of reducing apolipoprotein C-III
US9624492B2 (en)	2013-02-13	2017-04-18	Amarin Pharmaceuticals Ireland Limited	Compositions comprising eicosapentaenoic acid and mipomersen and methods of use thereof
US9662307B2 (en)	2013-02-19	2017-05-30	The Regents Of The University Of Colorado	Compositions comprising eicosapentaenoic acid and a hydroxyl compound and methods of use thereof
US9283201B2 (en)	2013-03-14	2016-03-15	Amarin Pharmaceuticals Ireland Limited	Compositions and methods for treating or preventing obesity in a subject in need thereof
US20140271841A1 (en)	2013-03-15	2014-09-18	Amarin Pharmaceuticals Ireland Limited	Pharmaceutical composition comprising eicosapentaenoic acid and derivatives thereof and a statin
US10966968B2 (en)	2013-06-06	2021-04-06	Amarin Pharmaceuticals Ireland Limited	Co-administration of rosiglitazone and eicosapentaenoic acid or a derivative thereof
US20150065572A1 (en)	2013-09-04	2015-03-05	Amarin Pharmaceuticals Ireland Limited	Methods of treating or preventing prostate cancer
US9585859B2 (en)	2013-10-10	2017-03-07	Amarin Pharmaceuticals Ireland Limited	Compositions and methods for lowering triglycerides without raising LDL-C levels in a subject on concomitant statin therapy
US10561631B2 (en)	2014-06-11	2020-02-18	Amarin Pharmaceuticals Ireland Limited	Methods of reducing RLP-C
WO2015195662A1 (en)	2014-06-16	2015-12-23	Amarin Pharmaceuticals Ireland Limited	Methods of reducing or preventing oxidation of small dense ldl or membrane polyunsaturated fatty acids
US10406130B2 (en)	2016-03-15	2019-09-10	Amarin Pharmaceuticals Ireland Limited	Methods of reducing or preventing oxidation of small dense LDL or membrane polyunsaturated fatty acids
US10966951B2 (en)	2017-05-19	2021-04-06	Amarin Pharmaceuticals Ireland Limited	Compositions and methods for lowering triglycerides in a subject having reduced kidney function
US11058661B2 (en)	2018-03-02	2021-07-13	Amarin Pharmaceuticals Ireland Limited	Compositions and methods for lowering triglycerides in a subject on concomitant statin therapy and having hsCRP levels of at least about 2 mg/L
PL4056176T3 (pl)	2018-09-24	2024-08-26	Amarin Pharmaceuticals Ireland Limited	Sposoby zmniejszania ryzyka zdarzeń krążeniowo-naczyniowych u osobnika
KR20240012390A (ko)	2021-04-21	2024-01-29	애머린 파마슈티칼스 아일랜드 리미티드	심부전의 위험을 감소시키는 방법

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US6197786B1 (en) *	1998-09-17	2001-03-06	Pfizer Inc	4-Carboxyamino-2-substituted-1,2,3,4-tetrahydroquinolines
US6462091B1 (en) *	1998-12-23	2002-10-08	G.D. Searle & Co.	Combinations of cholesteryl ester transfer protein inhibitors and HMG coA reductase inhibitors for cardiovascular indications
US20020028826A1 (en) *	2000-06-15	2002-03-07	Robl Jeffrey A.	HMG-CoA reductase inhibitors and method

2001
- 2001-07-23 EP EP01949825A patent/EP1309329A2/en not_active Ceased
- 2001-07-23 CN CNA018150667A patent/CN1735416A/zh active Pending
- 2001-07-23 JP JP2002518943A patent/JP2004506008A/ja not_active Withdrawn
- 2001-07-23 CZ CZ2003390A patent/CZ2003390A3/cs unknown
- 2001-07-23 MX MXPA03001419A patent/MXPA03001419A/es not_active Application Discontinuation
- 2001-07-23 AU AU2001270937A patent/AU2001270937A1/en not_active Abandoned
- 2001-07-23 HU HU0303083A patent/HUP0303083A3/hu unknown
- 2001-07-23 BR BR0113200-8A patent/BR0113200A/pt not_active IP Right Cessation
- 2001-07-23 AP APAP/P/2003/002743A patent/AP2003002743A0/en unknown
- 2001-07-23 CA CA002419406A patent/CA2419406A1/en not_active Abandoned
- 2001-07-23 WO PCT/IB2001/001309 patent/WO2002013797A2/en not_active Application Discontinuation
- 2001-07-23 SK SK174-2003A patent/SK1742003A3/sk not_active Application Discontinuation
- 2001-07-23 EA EA200300155A patent/EA200300155A1/ru unknown
- 2001-07-23 KR KR10-2003-7002220A patent/KR20030069983A/ko not_active Application Discontinuation
- 2001-07-23 IL IL15434801A patent/IL154348A0/xx unknown
- 2001-07-23 DZ DZ013409A patent/DZ3409A1/fr active
- 2001-08-14 PE PE2001000810A patent/PE20020340A1/es not_active Application Discontinuation
- 2001-08-14 PA PA20018525301A patent/PA8525301A1/es unknown
- 2001-08-14 SV SV2001000600A patent/SV2003000600A/es not_active Application Discontinuation
- 2001-08-14 TN TNTNSN01125A patent/TNSN01125A1/fr unknown
- 2001-08-14 UY UY26883A patent/UY26883A1/es not_active Application Discontinuation
- 2001-08-14 US US09/929,862 patent/US20020035125A1/en not_active Abandoned
2003
- 2003-01-27 IS IS6700A patent/IS6700A/is unknown
- 2003-02-03 BG BG107515A patent/BG107515A/xx unknown
- 2003-02-13 EC EC2003004478A patent/ECSP034478A/es unknown
- 2003-02-13 HR HR20030104A patent/HRP20030104A2/hr not_active Application Discontinuation
- 2003-02-14 NO NO20030725A patent/NO20030725D0/no unknown

Also Published As

Publication number	Publication date
JP2004506008A (ja)	2004-02-26
TNSN01125A1 (fr)	2005-11-10
ECSP034478A (es)	2003-03-31
SV2003000600A (es)	2003-01-13
KR20030069983A (ko)	2003-08-27
BG107515A (en)	2003-09-30
WO2002013797A3 (en)	2003-03-13
HRP20030104A2 (en)	2003-04-30
HUP0303083A2 (hu)	2003-12-29
WO2002013797A2 (en)	2002-02-21
PA8525301A1 (es)	2002-04-25
HUP0303083A3 (en)	2005-05-30
PE20020340A1 (es)	2002-05-10
CA2419406A1 (en)	2002-02-21
EP1309329A2 (en)	2003-05-14
MXPA03001419A (es)	2003-06-06
US20020035125A1 (en)	2002-03-21
CN1735416A (zh)	2006-02-15
AP2003002743A0 (en)	2003-03-31
BR0113200A (pt)	2003-09-16
SK1742003A3 (en)	2004-06-08
DZ3409A1 (fr)	2002-02-21
AU2001270937A1 (en)	2002-02-25
EA200300155A1 (ru)	2003-08-28
UY26883A1 (es)	2002-03-22
IL154348A0 (en)	2003-09-17
IS6700A (is)	2003-01-27
CZ2003390A3 (en)	2004-03-17

Publication	Publication Date	Title
NO20030725D0 (no)	2003-02-14	Terapeutisk kombinasjon av CETP-inhibitor og atorvastatin
DK1251848T3 (da)	2004-10-18	Gyraseinhibitorer og anvendelse deraf
NO20015773D0 (no)	2001-11-27	Forhindring og behandling av amyloidogen sykdom
NO20032668L (no)	2003-06-12	Gyraseinhibitorer og anvendelser derav
NO20020343D0 (no)	2002-01-22	Kaspase-inhibitorer og anvendelse derav
NO20022656D0 (no)	2002-06-05	Caspaseinhibitorer og anvendelse derav
NO20041582L (no)	2004-04-19	Antistoffinhibitorer av GDF-8 og anvendelse derav
NO20014560D0 (no)	2001-09-19	Quinasoliner og terapautisk anvendelse derav
NO20002784D0 (no)	2000-05-31	Forhindring og behandling av amyloidogen sykdom
DK1268425T3 (da)	2008-05-05	Carbamatcaspaseinhibitorer og anvendelse deraf
HUP0201463A3 (en)	2004-06-28	Cyclooxygenase-2 inhibitor compositions having rapid onset of therapeutic effect and their use
NO20015757L (no)	2001-12-20	Felles salt av amlopidin og atorvastatin
IS6477A (is)	2002-07-19	Afleiður piperazíns og piperadíns
IS7089A (is)	2003-12-22	Lyfjasamsetningar amlódipíns og atórvastatíns
NO20015274L (no)	2001-12-28	ACE-2 inhiberende forbindelser og fremgangsmåter for anvendelse derav
NO20040390L (no)	2004-01-29	Krystallinske former VI og VII av atorvastatinkalsium.
NO20015756D0 (no)	2001-11-26	Felles promedikamenter av amlodipin og atorvastatin
NO20030899D0 (no)	2003-02-26	Anvendelse av salmeterol og fluticasonpropionat kombinasjon
EP1309552A4 (en)	2005-07-20	COMPOUNDS AND INHIBITORS OF PHOSPHOLIPASES
DK1228026T3 (da)	2004-04-05	15-Hydroxyicosatetraensyrerelaterede forbindelser og fremgangsmåde til anvendelse
NO20011703L (no)	2001-10-08	Kondensator av ikke-brennbar og uhellsforhindrende type
NO20026148L (no)	2003-02-20	Medisiner for forhindring og behandling av neurodegenerative sykdommer
NO20032821D0 (no)	2003-06-19	Sea-trosy og beslektede fremgangsmåter
NO20042126L (no)	2004-06-23	Syntese av 2-aralkoksyadenosiner og 2-alkoksyadenosiner
IS6118A (is)	2001-10-19	Samvirk áhrif amlódípíns og atórvastatíns